Objective. Regulatory B cells that inhibit immune responses through interleukin-10 (IL-10) secretion (B10 cells) have been characterized in adult subjects with autoimmune disease. The aim of this study was to characterize B10 cells in individuals across the entire age range of normal human development and changes in their frequency and numbers in children with autoimmunity.
B10 cells (decreased by 39% and 48%, respectively), higher IFNg levels, and lower IL-21 levels in serum. IFNg inhibited, whereas IL-21 promoted, B cell IL-10 competence in vitro.
Conclusion. B10 cells, a functionally defined cell subset with a variable surface phenotype reflective of overall B cell development, transiently expand during childhood. B10 cell frequencies and numbers were decreased in children with autoimmunity, which may be explained in part by alterations in serum IFNg and IL-21 that differentially regulate B10 cell development.
Regulatory B cells that inhibit immune responses through the secretion of cytokines have been described in a variety of mouse models of autoimmunity and inflammation (1, 2) . A subset of B cells that are competent to express the negative regulatory cytokine interleukin-10 (IL-10) (B10 cells) is among those best studied. Because phenotypic markers unique to B10 cells have not been identified, these cells are defined by their IL-10 expression following appropriate in vitro stimulation (3, 4) . As in mice (5, 6) , the frequency of B10 cells in humans is low (3, 7) . Human regulatory B cells have been reported within B cell subsets expressing phenotypic markers associated with transitional B cells (8) (9) (10) (11) (12) , memory B cells (3, 9, 11, 13) , germinal center B cells (14) , and plasmablasts (13) . Although the functional importance of B10 cells is well described in mice, their role in human autoimmunity remains unclear. Among adult humans, B10 cell frequencies are increased or maintained in those with autoimmunity (3). However, defects in the size and/or functionality of various regulatory B cell compartments have also been reported (8, 10, 11, (15) (16) (17) (18) (19) (20) .
B10 cell frequencies and numbers are increased in newborn and aged mice (6) . Two studies have examined B10 cells in healthy children: one in cryopreserved cord blood samples (3) and one in the context of WiskottAldrich syndrome (21) . There are no studies characterizing B10 cells in individuals across the entire age range of normal human development. Common low-grade inflammatory conditions (such as hypertension or obesity) that potentially confound the assessment of immunologic parameters in adults are rare in children (22, 23) . Furthermore, the incidence of autoimmunity is lower in children compared with adults (24) (25) (26) (27) (28) (29) (30) , in contrast to the extensive autoantigen exposure associated with tissue remodeling during normal growth. Additionally, the surface phenotype of blood B cells changes with age during childhood and reflects overall changes in B cell development (31) (32) (33) . Thus, studies of B10 cells during human development offer unique opportunities to examine this regulatory subset during normal growth and in the context of autoimmunity and to better define the relationship between B10 cells and surface phenotype-defined developmental B cell subsets.
PATIENTS AND METHODS
Study design. The study protocol was approved by the Duke University Institutional Review Board (IRB), in compliance with the Declaration of Helsinki. Participants were recruited from the Research Triangle Area (North Carolina) between February 2012 and July 2015. Following written informed consent, samples were obtained from neonates (umbilical cords; n 5 4), healthy children (n 5 20), and healthy adults (n 5 16). An 11-month-old infant was recruited from the University of South Florida, under its IRB-approved protocol.
Children with autoimmune disease (n 5 52) included 25 with juvenile idiopathic arthritis (JIA), 13 with juvenile dermatomyositis (DM), 13 with systemic lupus erythematosus (SLE), and 1 with mixed connective tissue disease (MCTD). All children with SLE satisfied the American College of Rheumatology criteria for the classification of SLE (34) . Twelve of 13 children with juvenile DM had a diagnostic muscle biopsy and/or electromyography and satisfied the Bohan and Peter criteria (35) . The child with MCTD had myositis, lymphopenia, Raynaud's phenomenon, periungual telangiectasia, polyarthritis, parotitis, and positive serum autoantibodies (rheumatoid factor, anti-Smith, anti-RNP). All 24 children with JIA satisfied the International League of Associations for Rheumatology criteria (36) . Due to sample limitations, there were only 5 white blood cell (WBC) measurements, 14 B10 cell measurements, and 11 B101B10 progenitor (B10pro) cell measurements in adults, and only 24 B10 cell measurements and 23 B101B10pro cell measurements in children with JIA.
Exclusion criteria included systemic-onset JIA, intercurrent illness, surgical procedures or vaccination within 4 weeks, and treatment with rituximab, belimumab, or cyclophosphamide during the last 12 months. The demographics and study characteristics of the healthy children are shown in Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.39820/abstract), and the clinical data for children with autoimmune diseases are shown in Supplementary Table 2 .
Because a common disease activity assessment tool for JIA, juvenile DM, SLE, and MCTD is not available, the physician's global assessment as a continuous visual analog scale (VAS) score (0-10 cm) was used to assess disease activity and minimize bias due to the use of multiple disease activity assessment tools. One of 8 pediatric rheumatologists at the Duke Children's Health Center scored each participant following his or her ambulatory care visit and prior to any laboratory testing. Scores of ,1 were categorized as "inactive disease" and scores of $1 as "active disease."
Cell isolation and culture. Fresh human peripheral blood was collected in EDTA-coated Vacutainer tubes (BD Biosciences) and processed within 12 hours. WBC counts were measured with a Beckman Coulter automated counter. Serum was obtained after whole blood centrifugation and stored at -80 C. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation over a discontinuous gradient (Lymphoprep; AxisShield) and quantified manually using a hemocytometer. PBMCs were resuspended in culture medium (RPMI 1640 with 10% fetal calf serum, 200 units/ml penicillin, 200 mg/ml streptomycin, and 2 mM L-glutamine) and seeded in 48-well flat-bottomed tissue culture plates (Genesee Scientific) at a final volume of 1 ml (2 3 10 6 PBMCs/ml). Cultures were stimulated with CpG ODN 2006 (10 mg/ml; InvivoGen), human recombinant CD40L (1 mg/ ml; Insight Genomics), phorbol esters (phorbol myristate acetate [PMA]) (50 ng/ml; Sigma-Aldrich), ionomycin (1 mg/ml; SigmaAldrich), and brefeldin A (5 mg/ml; BioLegend), as indicated. Alternatively, commercially available magnetic separation-based negative selection kits were used to purify B cells (EasySep; StemCell Technologies) and CD41 T cells (Human CD41 T Cell Isolation Kit; Miltenyi Biotec). The following recombinant human proteins (100 ng/ml) were used to stimulate IL-10 production by B cells in vitro: IL-12, IL-21, IL-27, and IL-35-Fc fusion protein (all from BioLegend), and interferon-g (IFNg) (PeproTech).
Immunofluorescence staining and flow cytometric analysis. Mononuclear cells were stained using predetermined optimal concentrations of antibodies for cell surface staining, permeabilized (Cytofix/Cytoperm; BD Biosciences), and stained for intracellular IL-10, IFNg, granulocyte-macrophage colonystimulating factor (GM-CSF), or IL-1b expression, as previously described (3) . Fixable viability dyes (Live/Dead Fixable Violet Dead Cell Stain [Invitrogen] and Zombie Aqua [BioLegend]) were used to exclude dead cells. The following fluorochromeconjugated anti-human monoclonal antibodies (mAb) were used: IgM (clone MHM-88), IgD (clone IA6-2), CD3 (clone OKT3), CD4 (clone OKT4), CD5 (clone UCHT2), CD10 (clone HI10a), CD19 (clone HIB19), CD20 (clone 2H7), CD21 (clone Bu32), CD22 (clone HIB22), CD24 (clone ML5), CD38 (HIT2), CD44 (IM7), CD48 (BJ40), CD73 (AD2), CD360 (2G1-K12), GM-CSF (clone BVD2-21C11), IL-1b (clone H1b-98,) and IL-10 (clone JES3-9D7) (all from BioLegend), IgG (clone G18-145), CD27 (clone M-T271) and IFNg (clone B57) (BD PharMingen), IL-12 receptor b2 (IL-12Rb2; clone 305719) (R&D Systems), and CD1d (clone 51.1) and CD9 (clone eBioSN4) (eBioscience). Surface IgA was visualized using goat polyclonal antibody (Southern Biotech). Immunofluorescence was quantified using a FACSCanto II cytometer (BD Biosciences) and FlowJo version 10 software.
In vitro functional assays. Purified CD41 T cells (1 3 10 6 /ml) were cultured for 72 hours with soluble CD3 mAb (clone HIT3a) (1 mg/ml; BD PharMingen), CD40L (1 mg/ml; Insight Genomics), and CpG ODN 2006 (10 mg/ml; InvivoGen) in the presence or absence of purified B cells (1 3 10 6 /ml) (1:1 ratio) in 48-well flat-bottomed plates at a final volume of 1 ml. IL-10R-blocking mAb (clone 3F9) (5 mg/ml; BioLegend) or control rat IgG2a (clone KLH/G2a-1-1) (5 mg/ml; Southern Biotech) was added to the B cell-T cell cocultures, as indicated. During the last 5 hours, cultures were stimulated with PMA, ionomycin, and brefeldin A. Cells were then stained with fluorophore-conjugated mAb against CD3, CD4, CD19, and IFNg, followed by flow cytometric analysis, as described above. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles; the crosses inside the boxes represent the mean. C, Relationship between age and B10 or B101B10pro cell frequencies. Broken lines represent the upper and lower limits of the 99% confidence interval of fitted polynomial regression curves, with adults grouped as a single age point (201) . P values were calculated using the independent samples unpaired Mann-Whitney U test.
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Serum cytokine analysis. Serum IFNg, IL-10, and IL-21 concentrations in duplicate samples were quantified by ELISA MAX kits (BioLegend) according to the manufacturer's protocols, with results quantified using an Emax microplate reader (Molecular Devices). Four-parameter regression analysis was used to fit standard curves and calculate cytokine values in serum samples.
Statistical analysis. Two-sided tests were used for all comparisons. The alpha value was set at 0.05. All differences between groups were tested with the independent samples unpaired Mann-Whitney U test unless otherwise indicated. All statistical testing was performed using the IBM SPSS platform (version 22). Graphics were created with GraphPad Prism (version 7) and IBM SPSS statistics.
RESULTS
Transient expansion of the B10 cell compartment in childhood. The size of the B10 cell compartment (B10 cells and B10pro cells) was assessed (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39820/abstract) as previously described (3). B10 cells were defined by their capacity to express IL-10 after short-term (5 hours) ex vivo stimulation with PMA, ionomycin, and brefeldin A ( Figure 1A ). B10pro cells did not express IL-10 following short-term ex vivo stimulation (37) but acquired IL-10 competence following 48 hours of agonistic CD40 stimulation (CD40L) in vitro ( Figure 1A ); the addition of CpG further enhanced the acquisition of IL-10 competence (3). Adding brefeldin A alone during the last 5 hours served as a negative control for the 0.1-0.2% background staining, similar to the frequencies observed in IL-10-deficient mice (4, 6) .
Healthy children (n 5 20; ages 3-16 years) had significantly increased frequencies and numbers of B10 and B101B10pro cells ( Figure 1B ) when compared with healthy adults (ages 27-52 years). The mean frequencies of B10 and B101B10pro cells in children were increased by 1.7-fold and 2.4-fold, respectively, and the mean numbers of B10 and B101B10pro cells were increased by 3.9-fold and 5.7-fold, respectively. B10 cell measurements in 14 adults and B101B10pro measurements in 11 adults were representative of those in .100 healthy adults (3,7). Children had higher absolute lymphocyte counts, B cell frequencies, and B cell numbers compared with adults (see Supplementary Figure 2A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.39820/abstract). The B10 cell compartment size was similar in males and females (see Supplementary Figure 2B ). Expansion of the B101B10pro cell compartment was transient and peaked in middle childhood (ages 5-11 years); a less-prominent relationship with age was observed for B10 cells ( Figure 1C) . Thus, the B10 cell compartment expands transiently during childhood, with up to 30% of B cells in blood becoming competent to produce IL-10 in middle childhood.
Variable B10 cell surface phenotype reflective of overall B cell development. The surface phenotype of B10 cells in children was variable. B10 cells were enriched within the non-naive (IgD2), class-switched (IgG1 or IgA1) B cell compartments, indicating their prior exposure to antigen in vivo ( Figure 2A ). The frequency and density of B10 cell surface IgM, IgD, IgG, IgA, CD19, CD20, CD21, and CD22 expression were similar between subjects, whereas the expression and density of surface markers that dynamically change during B cell development and maturation, such as CD5, CD9, CD10, CD24, CD27, CD38, CD44, CD48, and CD73, were more varied between subjects. Compared with older children, neonates had low B10 and B101B10pro cell frequencies ( Figure 1C ) despite their higher frequencies of CD24 high CD38
high and lower frequencies of CD271 B cells (31) (32) (33) . Neonates and adults had similar B10 and B101B10pro cell frequencies, despite the dramatically different surface phenotypes of 228 KALAMPOKIS ET AL neonatal B cells (high immature/naive and transitional B cell frequencies) compared with high frequencies of memory B cells in the blood of adults (33) . As in adults (3), CD5 was a poor marker for B10 cells in children, and CD1d was generally not expressed by blood B cells ( Figure  2A ). In addition, the low frequencies of B10 and B10pro cells in cord blood ( Figure 1C ) contrast with the abundance of CD51 B cells in neonates (38) . Thus, although there are no cell surface markers specific for B10 cells, these cells were more prevalent within certain surface phenotype-defined B cell subsets, depending on the age of the individual. Limited or no expression of proinflammatory cytokines in the B10 cell compartment in children. Because B10 and B101B10pro cells cannot be visualized without PMA/ionomycin stimulation, we examined the possibility that these cells represent activated B cells expressing multiple cytokines in response to nonspecific in vitro stimulation. The B10 and B101B10pro cell expression profile of 3 proinflammatory cytokines was examined using purified B cells from 3 healthy children (Figures 3A-C and Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39820/abstract). In all 3 subjects, B10 cells did not express GM-CSF, IL-1b, or IFNg, while ,15% of B101B10pro cells expressed GM-CSF and ,5% expressed IL-1b or IFNg. Therefore, the B10 cell compartment in children has a specific cytokine expression profile, characterized by limited or no expression of proinflammatory cytokines.
Regulatory effect of B10 cells on IFNg expression by CD41 T cells in vitro. The high B101B10pro cell frequencies in children provided the unique opportunity to examine the regulatory effects of the entire B10 cell compartment, eliminating the need to fractionate B cell Contraction of the B10 cell compartment in children with autoimmunity. The size of the B10 cell compartment was compared between age-matched healthy children and children with autoimmunity (see Supplementary Figure 6A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39820/abstract). Most children with autoimmunity had significantly lower B10 cell frequencies and numbers when compared with healthy children ( Figure 5A ). Children with autoimmunity were further categorized into 2 groups, based on data clustering: 1) children with JIA excluding systemic-onset JIA (JIA group), and 2) children with Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39820/abstract). P values were calculated using the paired-sample t-test. MFI 5 mean fluorescence intensity (see Figure 1 for other definitions). 
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KALAMPOKIS ET AL juvenile DM, SLE, and MCTD (juvenile DM/SLE/MCTD group). B101B10pro cell frequencies and numbers were decreased only in the juvenile DM/SLE/MCTD group ( Figure 5A ). Children with juvenile DM/SLE/MCTD had lower absolute lymphocyte counts compared with healthy children, but there were no significant differences in B cell frequencies and numbers or WBC counts between disease groups (see Supplementary Figure 2C , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39820/abstract). Thus, the B10 cell compartment was contracted in children with autoimmunity, particularly in the juvenile DM/SLE/MCTD group. Expansion of the B10 cell compartment as active disease increases in children with juvenile DM/SLE/ MCTD. Because JIA, juvenile DM, SLE, and MCTD do not share a disease activity measure, the physician's global assessment was used to assess disease activity following age matching (see Supplementary Figure 6B , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39820/abstract). Both the frequencies and numbers of B10 and B101B10pro cells increased significantly during active disease in the group with juvenile DM/SLE/MCTD but not in the group with JIA ( Figure 5B ). Despite B101B10pro cell expansion during active disease in the group with juvenile DM/SLE/ MCTD, the frequencies and numbers of B10 and B101 B10pro cells remained below those in healthy children ( Figure 5B ). B101B10pro cell frequencies correlated linearly with the VAS scores ( Figure 5C ). A similar trend was observed when B101B10pro cell frequencies were followed up longitudinally in 4 children with juvenile DM and 2 children with SLE ( Figure 5D and Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39820/abstract). There were no significant differences between disease activity groups in WBC counts, absolute lymphocyte counts, and B cell frequencies or numbers (see Supplementary Figure 2D , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39820/abstract). Thereby, although the B10 cell compartment is contracted in children with autoimmunity, B10 cells nonetheless retain their ability to expand during active disease in children with juvenile DM and those with SLE.
Effects of medication on the B10 cell compartment. Each group of children with autoimmunity (JIA and juvenile DM/SLE/MCTD) was classified into 2 "medication subgroups" for each medication, based on whether or not the child was receiving the medication at the time of blood sampling (see Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39820/abstract). No significant differences in B10 or B101B10pro cell frequencies between medication subgroups were noted, with the exception of mycophenolate mofetil (MMF) in children with SLE. MMF-treated children had significantly higher B10 cell frequencies compared with children not treated with MMF (see Supplementary Figure 7A , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39820/abstract). B101B10pro cell frequencies were not significantly higher in MMF-treated children compared with children not treated with MMF (P 5 0.097) (see Supplementary Figure  7B ). MMF-treated children had lower B cell numbers compared with children who were not treated with MMF (see Supplementary Figure 7C ), but there were no significant differences in age distribution (see Supplementary  Figure 6C ), WBC counts, absolute lymphocyte counts, and B cell frequencies (see Supplementary Figures 7C and D) between MMF-treated children and children who were not treated with MMF. Therefore, MMF therapy or other treatments did not explain the contracted B10 cell compartment observed in children with autoimmunity.
High IFNg and low IL-21 serum levels in children with autoimmunity. Although inherently low in most subjects, serum IL-10 concentrations were highest in the juvenile DM/SLE/MCTD group and healthy adults ( Figure  6A ). Higher levels of IL-10 among adults and among children with systemic autoimmunity contrasted with their lower frequencies of blood B10 cells, but multiple cell types produce IL-10 and undoubtedly contribute to the serum IL-10 pool. In contrast, healthy children had significantly lower serum IFNg and higher IL-21 levels compared with children with autoimmunity and healthy adults ( Figure 6A ). However, serum cytokine levels did not correlate with the size of the B10 cell compartment between individuals in any group and regardless of disease activity. Consistent with this, IL-21 promoted, whereas IFNg inhibited, IL-10 expression by mouse B cells in vitro (40) . Therefore, the differences in serum cytokines could provide a partial explanation for the differences in the B10 cell compartment among our study populations.
IL-21 promotion and IFNg inhibition of B cell IL-10 competence. In view of the observed differences in serum levels of cytokines, along with the reported effects of IFNg (40) When both IL-21 and IFNg were added to cultures, the effects of IL-21 on IL-10 expression by B cells predominated ( Figure 6C and Supplementary Figure 8A) . Similar results were observed with B cells from healthy adults (Supplementary Figure 8C) . Thus, IL-10 production by B cells was predominantly and differentially regulated by IL-21 and IFNg, which may also influence the size of the B10 cell compartment in vivo.
DISCUSSION
The current study demonstrates that the B10 cell compartment in blood is uniquely expanded in children relative to newborns and adults. The frequency of B101 B10pro cells peaked (at ;30%) in middle childhood ( Figure 1C) , while the B10 cell compartment normally represents ,10% of blood B cells in newborns and adults (3). The increase observed in children did not correlate with the expansion of a specific phenotypically defined B cell subset ( Figure 2 and Supplementary Figure 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39820/abstract).
Despite differences between the B10 cell compartments in children and adults, B10 cells from children retained their regulatory capacity and down-regulated IFNg production by CD41 T cells through IL-10-dependent pathways in vitro (Figure 4 ). There were also significant reductions in the frequencies and numbers of B10 and B101B10pro cells in children with autoimmune disease, but their frequencies nonetheless increased significantly as disease severity increased in children with juvenile DM and those with SLE ( Figure 5 ). Dynamic changes in the size of the B10 cell compartment are likely to be functionally important, because small increases in the numbers of B10 and B10pro cells in mice during adoptive transfer experiments can reduce inflammation and autoimmune disease (5, 37, 40, 43) , while reducing B10 cell numbers enhances subsequent innate and adaptive immune responses (39, 44, 45) . Thus, alterations in the size of the B10 cell compartment in children may differentially affect tolerance regulation and autoimmune disease.
Human regulatory B cells have been reported within a diverse variety of surface phenotype-defined developmental B cell subsets (3, (8) (9) (10) (11) (12) (13) (14) . Although B10 and B10pro cells in adults express a CD24 high CD271 memorylike phenotype (3, 7) , the surface phenotype of B10 cells in children was variable, and expansion of the B10 cell compartment in children did not correlate with the normal agerelated shifts among B cell subsets (Figure 2 ). B10 cells from children were highly represented within the transitional CD101CD24 high CD38 high CD44 low B cell subset, and relatively few B10 cells from children simultaneously expressed CD27 and high levels of CD24. A lack of correlation between phenotypically defined developmental B cell subsets and IL-10-competent B cells is well documented in adults (31) (32) (33) .
The phenotypic variability of B10 cells during normal human development and their lack of correlation with surface phenotype-defined developmental B cell subsets highlight the concept that B10 cells are a unique B cell subset that is functionally programmed to produce IL-10 in response to appropriate B cell receptor (BCR) signals rather than representing a cell lineage or a specific stage of B cell development (2) . The transient capacity of B10 cells to express IL-10 following appropriate activation in mice is highlighted by their termination of IL-10 production prior to plasmablast and plasma cell differentiation (46) . Furthermore, both B10 and B101B10pro cells display a specific cytokine-expression profile, with limited or no expression of inflammatory cytokines such as GM-CSF (47), IL-1b, and IFNg ( Figure 3 ). Thus, their capacity to express IL-10 remains the most comprehensive marker for B10 and B10pro cell identification and function.
Blood B10 cell frequencies increased during childhood, but the more dramatic increase was observed in B10pro cells ( Figure 1C (Figure 6 ), as occurs in mice (40) . Remarkably, healthy children had lower serum IFNg concentrations, as previously documented (48, 49) , and higher serum IL-21 levels when compared with either children with autoimmunity or healthy adults ( Figure 6 ). Thereby, contraction of the B10pro cell compartment in children with autoimmunity would be expected due to differences in the in vivo cytokine milieu to which B cells are exposed, which would predictably lead to reduced B10 cell numbers. Thus, rather than representing inherent functional defects within the B10 cell compartment, increased serum IFNg concentrations in persons with autoimmune disease may reduce the size of the B10pro cell pool in children. Alterations in the cytokine milieu may similarly account for the alterations within regulatory B cell compartments that have been reported to underlie autoimmune disease in adults (8, 10, 18, 19) . Consistent with this hypothesis, human IL-21 deficiency results in autoimmune manifestations (50) . Given this and the higher levels of IL-21 in healthy children ( Figure 6A ), our hypothesis is that when stimulated with appropriate antigens plus cognate T cell help, B cells in children are more prone to acquiring IL-10 competence compared with B cells in adults.
B10 cells are developmentally and functionally distinct from regulatory T cells, but they work synergistically with regulatory T cells to control autoimmune disease manifestations in mice (39) . High frequencies of regulatory T cells in healthy children (age range 10 months to 11.4 years) compared with the frequencies in adolescents (age range 15.5 years to 20.9 years) and adults (age range 40.8 years to 63.3 years) were recently documented (51). Thus, regulatory B10 cell and regulatory T cell expansion during middle childhood may represent a mechanism for promoting tolerance during this unique stage of human development. Thereafter, blood B10 cell frequencies do not change remarkably in adults until they decrease substantially (,0.2%) in old age (7) . In contrast, the spleen B10 cell compartment in neonatal mice is expanded, contracts quickly thereafter, and remains stable through adulthood, but the frequencies increase in aged mice (6) . Thereby, immune tolerance mechanisms may be more prominent in children than in adults, especially prior to adolescence.
The B10 cell compartment can expand with autoimmune disease in both adult humans and mice (3, 6) and in individuals prone to developing chronic lymphocytic leukemia (7) . In fact, B10 and B10pro cell expansion in some adults with autoimmune disease mimics the level of expansion reported herein for children (3) . In contrast, however, the B10 cell compartment was significantly contracted in children with autoimmune disease ( Figure   5 ), and the frequencies of B10 cells in children with autoimmune disease resembled those normally observed in healthy adults (Figure 1) . Nonetheless, the B10 cell compartment remained dynamic, as B101B10pro cell frequencies showed a limited increase with disease activity in children with juvenile DM and SLE but returned to low levels as disease activity decreased ( Figure 5 ). B10 and B10pro cell frequencies are also significantly reduced in children with Wiscott-Aldrich syndrome relative to healthy children (21) . Although defects in the size and/or functional capacity of Breg cell compartments in adults may contribute to the development of autoimmunity (8, 10, 11, (15) (16) (17) (18) (19) (20) , the current results suggest the opposite possibility that autoimmunity and inflammation may contribute to the reduced size of the B10 cell compartment. It therefore remains premature to draw conclusions regarding the dynamic function of the B10 cell compartment until there is a better understanding of the factors regulating their numbers and function in vivo during autoimmunity.
The IL-35 family of cytokines was recently shown to be involved in the development of B cell IL-10 competence (41, 42) . In our study, however, the IL-35 family cytokines (IL-12, IL-27, and IL-35-Fc fusion protein) did not promote IL-10-competent B cells ( Figure 6 and Supplementary Figure 8 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 39820/abstract). It is important to note that our approach for evaluating the involvement of IL-35 in the acquisition of human B cell IL-10 competence is different from the approach previously taken (41) , in which purified B cells were stimulated for 3 days with PMA and ionomycin prior to immunofluorescence staining for IL-10. Exposure of human B cells to PMA and ionomycin for .6 hours results in extensive B cell death (52) , and in all our assays only brief (5 hours) stimulation with PMA and ionomycin was used to maintain cell viability at the time of immunofluorescence staining for IL-10. Furthermore, in both approaches, IL-35-Fc fusion protein was used; this fusion protein may not have the same properties as those of native human IL-35. Therefore, the effects of IL-35 on human B cell IL-10 competence in vitro remain to be determined. Nevertheless, the potent effects of IL-21 on human B cell IL-10 competence in vitro open new horizons in the development of autologous B10 cell-based therapies (40) .
In conclusion, this is the first study to characterize B10 cells across the entire age range of human development, and documents that the size of the B10 cell compartment varies during normal human development and expands transiently in childhood. The peak of B10 cell compartment expansion occurs during middle childhood, when linear growth rates are lowest (53) , suggesting that B10 cells are particularly important in the regulation of immune 236 KALAMPOKIS ET AL tolerance prior to the pubertal growth spurt. The B10 cell compartment responds dynamically to inflammation in both children with juvenile DM/SLE ( Figure 5 ), adults (3, 7) , and mice (7, 37) , indicating that B10 cell development in vivo may be regulated by antigen exposure and select cytokines. Despite the expanded B10 cell compartment in healthy children, serum IL-10 levels remained low in comparison with those in adults and children with juvenile DM/ SLE/MCTD ( Figure 6A ), indicating that other cells preferentially contribute to serum IL-10 levels, and consistent with the notion that B10 cells regulate immune responses within local microenvironments rather than through the provision of systemic IL-10 (40). The identification of therapies that restore or augment the B10 cell compartment will clarify these issues and may provide attractive strategies for modulating immune responses and autoimmunity in the future.
